Tags:Sotigalimab 代理商,Sotigalimab 价格,Sotigalimab 供应商， Sotigalimab supplier,Sotigalimab purchase,Sotigalimab 购买,Sotigalimab 销售
Description
The FDA has granted an orphan drug designation to sotigalimab (APX005M) as a potential therapeutic option for patients with soft tissue sarcoma, according to announcement from Apexigen Inc., the drug developer. A novel, humanized monoclonal antibody, sotigalimab was designed stimulate antitumor immune response and to target CD40, which is a key co-stimulatory receptor that serves to activate innate and adaptive immune systems. When sotigalimab binds to CD40 on antigen-presenting cells, it induces a multifaceted immune response that brings several components of the immune system together to attack the cancer.
Catalog No.
DHD68911
Host species
Humanized
Species reactivity
Human
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
2.54 mg/ml
Purity
>95%
Clonality
Monoclonal
Isotype
IgG1-Kappa
Applications
Research Grade Biosimilar
Target
Tumor necrosis factor receptor superfamily member 5, B-cell surface antigen CD40, Bp50, CD40L receptor, TNFRSF5, CDw40, CD40
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
P25942
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
APX005M, APX-005, APX-005-M, APX-005M, CAS: 2305607-45-6
Note
For research use only. Not suitable for clinical or therapeutic use.
关键字： Sotigalimab;2305607-45-6;Bp50;CDw40;
武汉佰乐博生物（Biolab Reagents）由五位毕业于华中科技大学，华中农业大学，武汉大学等知名高校，且具有二十年工作经验的生命科学领域顶级研究者创立于2021年，凭借丰富的产品开发经验，利用全球领先的技术平台，引进和整合全球高品质的蛋白、抗体和试剂盒产品。目前，佰乐博生物作为法国AntibodySystem在亚洲的独家总代理，提供近30,000种生命科学试剂，核心产品涵盖蛋白、抗体和试剂盒，旨在为科研工作者提供专业、全面、可靠的试剂支持，推动生命科学研究的深入发展。